Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Equity to Asset 0.53
DXR's Equity to Asset is ranked lower than
61% of the 170 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 0.59 vs. DXR: 0.53 )
Ranked among companies with meaningful Equity to Asset only.
DXR' s 10-Year Equity to Asset Range
Min: 0.42  Med: 0.72 Max: 0.85
Current: 0.53
0.42
0.85
Interest Coverage 3.93
DXR's Interest Coverage is ranked lower than
83% of the 104 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 38.48 vs. DXR: 3.93 )
Ranked among companies with meaningful Interest Coverage only.
DXR' s 10-Year Interest Coverage Range
Min: 3.93  Med: 13.00 Max: 25.28
Current: 3.93
3.93
25.28
F-Score: 4
M-Score: -2.02
WACC vs ROIC
4.29%
2.05%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) 67.05
DXR's Operating margin (%) is ranked higher than
99% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. DXR: 67.05 )
Ranked among companies with meaningful Operating margin (%) only.
DXR' s 10-Year Operating margin (%) Range
Min: -766.67  Med: -303.07 Max: 281.17
Current: 67.05
-766.67
281.17
Net-margin (%) -70.83
DXR's Net-margin (%) is ranked lower than
89% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.58 vs. DXR: -70.83 )
Ranked among companies with meaningful Net-margin (%) only.
DXR' s 10-Year Net-margin (%) Range
Min: -496.96  Med: -25.26 Max: 858.77
Current: -70.83
-496.96
858.77
ROE (%) -3.83
DXR's ROE (%) is ranked lower than
66% of the 173 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.07 vs. DXR: -3.83 )
Ranked among companies with meaningful ROE (%) only.
DXR' s 10-Year ROE (%) Range
Min: -26.26  Med: -0.59 Max: 30.74
Current: -3.83
-26.26
30.74
ROA (%) -2.11
DXR's ROA (%) is ranked lower than
64% of the 183 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.52 vs. DXR: -2.11 )
Ranked among companies with meaningful ROA (%) only.
DXR' s 10-Year ROA (%) Range
Min: -12.35  Med: -0.49 Max: 16.86
Current: -2.11
-12.35
16.86
Revenue Growth (3Y)(%) -2.80
DXR's Revenue Growth (3Y)(%) is ranked lower than
74% of the 149 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 5.00 vs. DXR: -2.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
DXR' s 10-Year Revenue Growth (3Y)(%) Range
Min: -60.3  Med: 10.65 Max: 38.7
Current: -2.8
-60.3
38.7
» DXR's 10-Y Financials

Financials


Revenue & Net Income
Equity & Asset
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

DXR Guru Trades in Q2 2014

Jim Simons 47,400 sh (+0.64%)
» More
Q3 2014

DXR Guru Trades in Q3 2014

Jim Simons 47,500 sh (+0.21%)
» More
Q4 2014

DXR Guru Trades in Q4 2014

Jim Simons 48,500 sh (+2.11%)
» More
Q1 2015

DXR Guru Trades in Q1 2015

Jim Simons 50,700 sh (+4.54%)
» More
» Details

Insider Trades

Latest Guru Trades with DXR

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.04
DXR's P/B is ranked higher than
85% of the 169 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.81 vs. DXR: 1.04 )
Ranked among companies with meaningful P/B only.
DXR' s 10-Year P/B Range
Min: 0.79  Med: 1.12 Max: 2.68
Current: 1.04
0.79
2.68
P/S 18.54
DXR's P/S is ranked lower than
94% of the 187 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.79 vs. DXR: 18.54 )
Ranked among companies with meaningful P/S only.
DXR' s 10-Year P/S Range
Min: 14  Med: 28.54 Max: 101.65
Current: 18.54
14
101.65
EV-to-EBIT 51.01
DXR's EV-to-EBIT is ranked lower than
85% of the 117 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 21.92 vs. DXR: 51.01 )
Ranked among companies with meaningful EV-to-EBIT only.
DXR' s 10-Year EV-to-EBIT Range
Min: -16.2  Med: 0.60 Max: 59.1
Current: 51.01
-16.2
59.1
Shiller P/E 15.04
DXR's Shiller P/E is ranked higher than
87% of the 80 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 31.27 vs. DXR: 15.04 )
Ranked among companies with meaningful Shiller P/E only.
DXR' s 10-Year Shiller P/E Range
Min: 5.93  Med: 8.04 Max: 52.94
Current: 15.04
5.93
52.94
Days Sales Outstanding 86.08
DXR's Days Sales Outstanding is ranked lower than
78% of the 154 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 62.15 vs. DXR: 86.08 )
Ranked among companies with meaningful Days Sales Outstanding only.
DXR' s 10-Year Days Sales Outstanding Range
Min: 4.44  Med: 53.41 Max: 243.33
Current: 86.08
4.44
243.33

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 0.46
DXR's Dividend Yield is ranked lower than
88% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.40 vs. DXR: 0.46 )
Ranked among companies with meaningful Dividend Yield only.
DXR' s 10-Year Dividend Yield Range
Min: 0.37  Med: 3.33 Max: 11.38
Current: 0.46
0.37
11.38
Dividend growth (3y) -68.90
DXR's Dividend growth (3y) is ranked lower than
91% of the 54 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 9.10 vs. DXR: -68.90 )
Ranked among companies with meaningful Dividend growth (3y) only.
DXR' s 10-Year Dividend growth (3y) Range
Min: 0  Med: 0.00 Max: -20.6
Current: -68.9
Yield on cost (5-Year) 0.02
DXR's Yield on cost (5-Year) is ranked lower than
100% of the 148 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.68 vs. DXR: 0.02 )
Ranked among companies with meaningful Yield on cost (5-Year) only.
DXR' s 10-Year Yield on cost (5-Year) Range
Min: 0.02  Med: 0.14 Max: 0.49
Current: 0.02
0.02
0.49
Share Buyback Rate 1.20
DXR's Share Buyback Rate is ranked higher than
86% of the 132 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: -2.40 vs. DXR: 1.20 )
Ranked among companies with meaningful Share Buyback Rate only.
DXR' s 10-Year Share Buyback Rate Range
Min: 11.2  Med: 0.75 Max: 0.2
Current: 1.2

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 1.04
DXR's Price/Tangible Book is ranked higher than
88% of the 147 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 3.93 vs. DXR: 1.04 )
Ranked among companies with meaningful Price/Tangible Book only.
DXR' s 10-Year Price/Tangible Book Range
Min: 0.83  Med: 1.52 Max: 2.63
Current: 1.04
0.83
2.63
Price/Median PS Value 0.66
DXR's Price/Median PS Value is ranked higher than
85% of the 162 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 1.26 vs. DXR: 0.66 )
Ranked among companies with meaningful Price/Median PS Value only.
DXR' s 10-Year Price/Median PS Value Range
Min: 0.25  Med: 1.62 Max: 8.7
Current: 0.66
0.25
8.7
Earnings Yield (Greenblatt) (%) 1.93
DXR's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 179 Companies
in the Global Medical Instruments & Supplies industry.

( Industry Median: 2.90 vs. DXR: 1.93 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
DXR' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: 1.7  Med: 64.10 Max: 38792.9
Current: 1.93
1.7
38792.9

Business Description

Industry: Medical Instruments & Equipment » Medical Instruments & Supplies
Compare:WST, BAX, COV, TMO, COO » details
Daxor Corp was originally incorporated in New York State as Iatric Corporation in May 1971for cryobanking services and continues these services through its wholly-owned subsidiary, Scientific Medical Systems. In October 1971, the name Iatric Corporation was changed to Idant Corporation. In May 1973, the name Idant Corporation was changed to Daxor Corporation. It is a medical device manufacturing Company, which offers additional biotech services, such as cryobanking, through its wholly owned subsidiary Scientific Medical Systems Corp. The main focus of the Company has been the development and marketing of an instrument that rapidly and accurately measures human blood volume. This instrument is used in conjunction with a single use diagnostic injection and collection kit that the Company also sells to its customers. The Company's main focus has been on the development of the BVA-100(r) Blood Volume Analyzer, an instrument that rapidly and accurately measures human blood volume. The instrument is used in conjunction with Volumex(r), a single-use radiopharmaceutical diagnostic injection and collection kit. The BVA-100 has also been used to aid in the diagnosis and treatment of polycythemia, hypertension, anemia, chronic fatigue, and to aid in presurgical evaluation. Additional possible uses include management of kidney dialysis, ultrafiltration, and blood optimization for elective surgery. The Company's marketing of the blood volume analyzer could be divided roughly into three phases: initial beta testing at local facilities, late-stage beta testing at nationally recognized institutions - with an emphasis on developing studies for publication, and marketing of the instrument for clinical use. During late-stage beta testing and the marketing phase, the instrument continued to experience a number of major technical improvements and alternations. It competes for customers based on a variety of factors, including reputation, customer service, performance, expertise, price and scope of service offerings.
» More Articles for DXR

Headlines

Articles On GuruFocus.com
Daxor Receives Notification of Patent Approval and Issues an Update on its Stock Buyback Program Mar 17 2015 
Daxor Corporation Appoints Michael Feldschuh as Executive Vice President Dec 18 2014 
Daxor Corporation Announces a Major Study With the Mayo Clinic Dec 11 2014 
Daxor Corporation Announces Payment of a Dividend Nov 17 2014 
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating Bloo Nov 03 2014 
Daxor Corporation Announces Research Agreement With Virginia Commonwealth University on Burn Patient Oct 21 2014 
3 Cheap Health Care Dividend Stocks with Huge Potential to Grow Dividends Oct 02 2013 
Weekly 3-Year Low Stocks: PBR, NJ, DWA, DXR Feb 10 2013 
High Yields In Healthcare Sector May 26 2011 
Daxor Corp Reports Operating Results (10-Q) Nov 12 2010 

More From Other Websites
Daxor Announces the receipt of a contract for the placement of a BVA-100 Blood Volume Analyzer at... Jun 23 2015
Daxor Announces the Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer at... Jun 23 2015
Daxor Announces the Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer at... Apr 28 2015
Daxor Announces the Receipt of a Contract for the Placement of a BVA-100 Blood Volume Analyzer at... Apr 28 2015
Daxor Receives Two Patents, One for Measurement of Total Body Albumin and a Second Patent for... Apr 09 2015
Daxor Receives Two Patents, One for Measurement of Total Body Albumin and a Second Patent for... Apr 09 2015
Daxor Receives Notification of Patent Approval and Issues an Update on its Stock Buyback Program Mar 17 2015
Daxor Receives Notification of Patent Approval and Issues an Update on its Stock Buyback Program Mar 17 2015
Daxor Corporation Announces Placement of Two BVA-100 Blood Volume Analyzers Mar 16 2015
Daxor Corporation Announces Placement of Two BVA-100 Blood Volume Analyzers Mar 13 2015
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2014 Mar 03 2015
Daxor Corporation Announces Filing of Form N-CSR for December 31, 2014 Feb 27 2015
Daxor Corporation Announces Major Research Studies Jan 30 2015
Daxor Corporation Appoints Michael Feldschuh as Executive Vice President Dec 18 2014
Daxor Corporation Announces A Major Study with the Mayo Clinic Dec 11 2014
Daxor Corporation Announces a Major Study With the Mayo Clinic Dec 11 2014
Daxor Corporation Announces Payment of a Dividend Nov 17 2014
Daxor Corporation Announces Payment of a Dividend Nov 17 2014
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating... Nov 03 2014
Daxor Announces Publication of a Study Comparing Two Widely Used Surrogate Tests for Estimating... Nov 03 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK